What it's for (Indications)
- Betamethasone + Gentamicin combination is indicated for the topical treatment of inflammatory dermatoses that are complicated by, or threatened with, secondary bacterial infection.
- This encompasses a range of corticosteroid-responsive skin conditions including, but not limited to, atopic eczema, discoid eczema, stasis dermatitis, psoriasis (excluding widespread plaque psoriasis), contact dermatitis, seborrheic dermatitis, and neurodermatitis, where there is a concurrent bacterial component.
- The presence of infection should be confirmed or strongly suspected, and the bacterial pathogen should be susceptible to gentamicin.
- This formulation provides both anti-inflammatory and antibacterial actions, addressing both the dermatological inflammation and the associated bacterial infection, thereby offering a comprehensive therapeutic approach to such complex skin conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | This medication is typically applied as a thin film to the affected skin area once or twice daily, depending on the severity of the condition and clinical response, or as directed by a healthcare professional. Application should involve gently rubbing the cream or ointment into the skin until it is evenly distributed. The duration of treatment should generally be limited, usually not exceeding 7 to 14 days, to minimize the potential for local and systemic side effects associated with potent corticosteroids and to reduce the risk of antibiotic resistance. Prolonged use, application to large surface areas, or use under occlusive dressings is strongly discouraged, particularly in pediatric patients, due to the increased risk of systemic absorption and associated adverse events. Treatment should be re-evaluated if no improvement is observed within this timeframe. |
Safety & Warnings
Common Side Effects
- Topical application of betamethasone + gentamicin can lead to a variety of local and, in some cases, systemic side effects.
- Local adverse reactions commonly reported with corticosteroids include skin atrophy, striae, telangiectasia, burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, and miliaria.
- With gentamicin, local irritation, itching, burning, and allergic contact dermatitis may occur.
- Systemic absorption of betamethasone, especially with extensive use, prolonged treatment, or under occlusive dressings, may lead to hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- While rare with topical use, significant systemic absorption of gentamicin, particularly on large areas of broken skin, carries a theoretical risk of ototoxicity and nephrotoxicity, especially in susceptible individuals or with co-administration of other nephrotoxic/ototoxic drugs.
Serious Warnings
- Black Box Warning: While Betamethasone + Gentamicin topical formulations do not typically carry an official FDA Black Box Warning, several critical safety considerations necessitate a 'Serious Warnings' advisement due to potential severe risks. **Serious Warnings:** **1. Systemic Corticosteroid Effects:** Prolonged use, application to large surface areas, or use under occlusive dressings, particularly in infants and children, can lead to significant systemic absorption of betamethasone. This can result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. HPA axis suppression can lead to secondary adrenal insufficiency, which may be life-threatening. Pediatric patients are more susceptible due to a larger skin surface area to body weight ratio. Discontinuation should be gradual if prolonged use has occurred. **2. Potential for Nephrotoxicity and Ototoxicity with Gentamicin:** Although rare with topical application on intact skin, significant systemic absorption of gentamicin, especially when applied to large body surface areas, denuded skin, or for prolonged periods, carries a theoretical risk of nephrotoxicity and ototoxicity. This risk is heightened in patients with pre-existing renal impairment or those concurrently receiving other systemic nephrotoxic or ototoxic medications. Patients should be monitored for signs of systemic toxicity if extensive use is unavoidable. **3. Microbial Resistance and Superinfection:** The prolonged or widespread use of topical gentamicin can lead to the overgrowth of non-susceptible organisms, including fungi, and the development of bacterial resistance. Should superinfection occur, the medication should be discontinued, and appropriate alternative antifungal or antibacterial therapy must be initiated promptly. Indiscriminate use of antibiotics contributes to the global challenge of antimicrobial resistance. **4. Local Irreversible Skin Changes:** Potent topical corticosteroids, including betamethasone, can cause irreversible local adverse reactions with prolonged use, such as skin atrophy, permanent striae, telangiectasias, and purpura, particularly in delicate skin areas like the face and intertriginous zones. Regular assessment of the skin condition is crucial to mitigate these risks.
- This combination product should be used with extreme caution, particularly in infants and children, due to their increased susceptibility to systemic absorption and HPA axis suppression from topical corticosteroids.
- Prolonged use, application to large body surface areas, or use under occlusive dressings significantly increases the risk of systemic adverse effects, including adrenal suppression, Cushing's syndrome, and growth retardation in pediatric patients.
- Avoid contact with eyes and mucous membranes, as topical corticosteroids can exacerbate glaucoma and cataracts if applied near the eyes.
- Superinfection with non-susceptible organisms, including fungi, may develop with prolonged or inappropriate use of the gentamicin component; discontinue use and initiate appropriate antifungal or alternative antibacterial therapy if this occurs.
- The development of bacterial resistance to gentamicin is a concern with extended use.
- Not for ophthalmic or otic use unless specifically formulated for such.
- Exercise caution in patients with impaired renal function if significant systemic absorption is anticipated, as gentamicin elimination may be reduced, increasing the risk of toxicity.
How it Works (Mechanism of Action)
The therapeutic action of betamethasone + gentamicin arises from the combined effects of its two active components. Betamethasone is a potent synthetic corticosteroid that exerts its anti-inflammatory, antipruritic, and vasoconstrictive properties by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. This effectively suppresses the inflammatory response in the skin. Gentamicin is a broad-spectrum aminoglycoside antibiotic that functions by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with bacterial protein synthesis, leading to misreading of the mRNA code and subsequent production of non-functional proteins, ultimately resulting in bactericidal activity against a wide range of Gram-negative bacteria (e.g., Pseudomonas aeruginosa, Escherichia coli) and some Gram-positive bacteria (e.g., Staphylococcus aureus), making it effective against common skin pathogens.
Commercial Brands (Alternatives)
No other brands found for this formula.